LEUCEMIA GRANULOCITICA CRONICA PDF

Chronic Myeloide Leukemia: natural history and classification. Chiattone II. CML is a clonal disease characterized by balanced translocation between chromosomes 9 and 22 Philadelphia chromosome. The disease is characterized by a triphasic course that includes a chronic phase CP , an accelerated phase AP and an acute or blastic phase BP. Unless the disease is controlled or eliminated, patients progress to AP and BF in variable periods of time.

Author:Kagasida Akinokazahn
Country:Colombia
Language:English (Spanish)
Genre:History
Published (Last):18 November 2016
Pages:415
PDF File Size:2.40 Mb
ePub File Size:2.39 Mb
ISBN:457-4-88456-858-5
Downloads:63289
Price:Free* [*Free Regsitration Required]
Uploader:Tejas



Chronic Myeloide Leukemia: natural history and classification. Chiattone II. CML is a clonal disease characterized by balanced translocation between chromosomes 9 and 22 Philadelphia chromosome. The disease is characterized by a triphasic course that includes a chronic phase CP , an accelerated phase AP and an acute or blastic phase BP. Unless the disease is controlled or eliminated, patients progress to AP and BF in variable periods of time.

Several staging classification systems are used for CML all of which were designed in the pre-imatinib era. In this article we discuss the natural history of CML and phase definitions according to the most useful criteria. Key words: CML; classification; staging; prognostic factors; disease progression. De fato, o conceito de FA tem mudado desde que os estudos dessas drogas se iniciaram. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.

Mayo Clin Proc. Bortolheiro TC. Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: study of 98 cases. Clinical heterogeneity in chronic myeloid leukemia refleting biological diversity in normal persons. Br J Haematol. Beutler E.

Discrepancies between genotype and phenotype in hematolgy: an important frontier. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. Bain BJ. Diagnosis from the blood smear. N Engl J Med. Staging of chronic myeloid leukemia in the imatinib era. An evaluation of the World Health Organization proposal. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin hematol. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.

Leuk Lymphoma. The molecular biology of chronic myeloid leukemia. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License. Services on Demand Journal. How to cite this article.

HCPL 7800A PDF

Aspetti citogenetici della leucemia mieloide cronica

We'd like to understand how you use our websites in order to improve them. Register your interest. Il cromosoma di Filadelfia Ph 1 rappresenta un elemento distintivo marker della maggior parte delle forme di leucemia mieloide cronica LMC. However, some particular patterns of CML such as the infantile ones, the form with mature polynucleates of Emil-Weil type, the eosinophilic forms are as a rule characterized by the absence of Philadelphia chromosome. During the blastic crises of CML Ph I may be associated with other structural chromosomal anomalies which prove the clonal evolution of some advantaged proliferative lines. Diseases different from CML may occasionally show Ph I -like chromosomes; it has been therefore suggested to consider the Philadelphia chromosome not as a CML distinguishing chromosome, but rather as a marker of myeloproliferative syndromes. Finally, the relationships between Ph I and stem cells would demonstrate that Ph I may appear at the level of very undifferentiated cells; on the other hand the succession of pathogenetic events involved in the determinism of the anomaly is still controversial.

AMIE SYLLABUS SECTION A DIPLOMA STREAM PDF

¿Qué avances hay en la investigación de la leucemia mieloide crónica?

Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy. See our Privacy Policy and User Agreement for details. Published on Sep 14, SlideShare Explore Search You. Submit Search.

ASROCK K7S8X MANUAL PDF

¿Qué causa la leucemia mieloide crónica?

.

Related Articles